COMPANY
BeOne Medicines
FDA-approved therapeutic company
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Manager, Finance Master Data Management | Warsaw | Oct 23, 2026 | Oct 16, 2026 |
| (Senior) Clinical Site Payment Associate | Seoul | Oct 23, 2026 | Oct 16, 2026 |
| Medical Science Liaison | Seoul | Oct 23, 2026 | Oct 16, 2026 |
| Associate Director, Health Technology Assessment Operations | Basel | Oct 23, 2026 | Oct 23, 2026 |
| Director, Value Demonstration & Access Evidence Strategy (Hematology) | Basel | Oct 23, 2026 | Oct 23, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2 trial (NCT07733180, actual start Sep 14, 2026) (+3 other new trials); 53 clinical-operations roles open. ClinicalTrials.gov NCT07733180 (Sep 14, 2026)
Evidence (4 events)
- Sep 14, 2026 · ClinicalTrials.gov NCT07733180
leadSponsor.name='BeOne Medicines'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-14,type:ACTUAL}; studyFirstPostDate=2026-07-29; briefTitle='A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC' - Sep 25, 2026 · ClinicalTrials.gov NCT07820891
leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-25,type:ACTUAL}; studyFirstPostDate=2026-09-15; briefTitle='A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395' - Sep 2, 2026 · ClinicalTrials.gov NCT07746141
leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-09-02,type:ACTUAL}; studyFirstPostDate=2026-08-04; briefTitle='A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic So' - Jul 21, 2026 · ClinicalTrials.gov NCT07712640
leadSponsor.name='BeOne Medicines'; phases=['PHASE1']; overallStatus=RECRUITING; startDateStruct={date:2026-07-21,type:ACTUAL}; studyFirstPostDate=2026-07-17; briefTitle='A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in '
- Sep 14, 2026 · ClinicalTrials.gov NCT07733180
- Drug approval + hiring FDA novel approval for BEQALZI (NDA 220711, May 13, 2026); 89 manufacturing/quality or commercial roles open. FDA NDA 220711 (May 13, 2026)
Evidence (1 event)
- May 13, 2026 · FDA NDA 220711
openFDA drugsfda: application_number=NDA220711; sponsor_name='BEONE MEDICINES USA'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20260513; submission_class_code=TYPE 1; brand_name=['BEQALZI']
- May 13, 2026 · FDA NDA 220711
Timeline
- FDA FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/18, Aug 25, 2026. Applicant at approval: BeOne Medicines USA, Inc. source ↗
- FDA FDA New drug/biologic (novel): BEQALZI (sonrotoclax) — NDA220711, May 13, 2026. Applicant at approval: BeOne Medicines USA, Inc. Accelerated approval. source ↗
- FDA FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/13, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/10, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/9, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA FDA Original approval: BRUKINSA (zanubrutinib) — NDA218785/ORIG2, Jun 10, 2025. Applicant at approval: BeOne Medicines USA, Inc. Accelerated approval. source ↗
- FDA FDA Original approval: BRUKINSA (zanubrutinib) — NDA218785, Jun 10, 2025. Applicant at approval: BeOne Medicines USA, Inc. source ↗
FDA records (last 2 years)
- FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/18, Aug 25, 2026. Applicant at approval: BeOne Medicines USA, Inc. source ↗
- FDA New drug/biologic (novel): BEQALZI (sonrotoclax) — NDA220711, May 13, 2026. Applicant at approval: BeOne Medicines USA, Inc. Accelerated approval. source ↗
- FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/13, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/10, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA New indication / efficacy supplement: TEVIMBRA (tislelizumab-jsgr) — BLA761232/9, Dec 9, 2025. Applicant at approval: BeOne Medicines U.S.A., Inc. source ↗
- FDA Original approval: BRUKINSA (zanubrutinib) — NDA218785/ORIG2, Jun 10, 2025. Applicant at approval: BeOne Medicines USA, Inc. Accelerated approval. source ↗
- FDA Original approval: BRUKINSA (zanubrutinib) — NDA218785, Jun 10, 2025. Applicant at approval: BeOne Medicines USA, Inc. source ↗
Open jobs 276
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Manager, Finance Master Data Management | Warsaw | Oct 23, 2026 | Oct 16, 2026 | Not stated |
| (Senior) Clinical Site Payment Associate | Seoul | Oct 23, 2026 | Oct 16, 2026 | Not stated |
| Medical Science Liaison | Seoul | Oct 23, 2026 | Oct 16, 2026 | Not stated |
| Associate Director, Health Technology Assessment Operations | Basel | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Director, Value Demonstration & Access Evidence Strategy (Hematology) | Basel | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Global Study Management (Senior) Associate (Global CTA) | 2 locations (listed on the posting) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| (Senior) Study Start-up Specialist | Japan | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Director, Field Analytics, Hematology | Remote (US) | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| (Sr) Account Executive - Taichung | Taichung Remote | Oct 23, 2026 | Oct 23, 2026 | Not stated |
| Senior Agiloft Configurations & Process Analyst | Warsaw | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Business Analytics & Insights | Spain Remote | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Key Account Manager - Hematology | Germany Remote | Oct 22, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Digital Clinical Operations | Canada Remote | Oct 22, 2026 | Oct 22, 2026 | Not stated |
| Principal Scientist, Early Discovery & Immune Cell Engineering | San Carlos | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Clinical Research Associate I (CRA I) - Oncology | Remote (US) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Manager, Patient Services Promotions | Remote (US) | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Manager, Global Procurement Operations | Warsaw | Oct 22, 2026 | Oct 23, 2026 | Not stated |
| Senior Director, Global Medical Affairs Disease Area Lead, Solid Tumors | Remote (US) | Oct 21, 2026 | Oct 16, 2026 | Not stated |
| Senior Data Scientist | Remote (US) | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Senior Administrative Assistant | Hopewell | Oct 20, 2026 | Oct 16, 2026 | Not stated |
| Clinical Research Associate | Milan | Oct 20, 2026 | Oct 16, 2026 | Not stated |
| Clinical Research Associate | Germany Remote | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Senior Manager, Regulatory Affairs, Japan | Japan | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Associate Director, Good Clinical Practice (GCP) Audits and Inspections | 4 locations (listed on the posting) | Oct 20, 2026 | Oct 20, 2026 | Not stated |
| Senior OTC Specialist – Credit Management | Warsaw | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Clinical Research Associate | Germany Remote | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Senior Clinical Research Associate | São Paulo | Oct 20, 2026 | Oct 21, 2026 | Not stated |
| Director, Head of Patient Recruitment and Retention, Americas | Remote (US) | Oct 19, 2026 | Oct 16, 2026 | Not stated |
| Senior Medical Director, Product Safety Physician Lead | Remote (US) | Oct 19, 2026 | Oct 16, 2026 | Not stated |
| Sales & Account Representative Hematology & Oncology (CABA) | Argentina Remote | Oct 19, 2026 | Oct 17, 2026 | Not stated |
| Senior Manager, Global Value, Access & Pricing, Hematology | Basel | Oct 19, 2026 | Oct 18, 2026 | Not stated |
| Quality Control Specialist, Medical Writing | Remote (US) | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Marketing Lead Solid Tumors, Germany | Germany Remote | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Associate Director, Digital Execution | Remote (US) | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Country Medical Director, Switzerland | Basel | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Director, Patient Advocacy, Europe, | 2 locations (listed on the posting) | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Associate Director, Regulatory Affairs - UK & Ireland | United Kingdom Remote | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Associate Director; Global Value & Access; Hematology | Basel | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Manager, Regulatory Affairs (Taiwan) | Taipei Xinyi | Oct 16, 2026 | Oct 16, 2026 | Not stated |
| Sr. Principal Software and AI Engineer | Remote (US) | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Director, Medical Digital Solutions | Remote (US) | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Associate Director, Patient Services and Distribution Case Management - Great Lakes/Northeast Region | Remote (US) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Vice President, Global Product Team Leader, Lung Cancer | Remote (US) | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Clinical Study Manager | São Paulo | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| (Senior) Associate, Clinical Site Budget Planning | Taipei Xinyi | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Training Manager, Customer Excellence, Japan | Japan | Oct 15, 2026 | Oct 16, 2026 | Not stated |
| Senior Global Clinical Study Manager | Remote (US) | Oct 14, 2026 | Oct 16, 2026 | Not stated |
| Director, Communications, Europe | Basel | Oct 14, 2026 | Oct 16, 2026 | Not stated |
| Franchise Head Solid Tumor, Director – Spain | Spain Remote | Oct 14, 2026 | Oct 16, 2026 | Not stated |
| Senior Manager, Regulatory Affairs - US | Remote (US) | Oct 14, 2026 | Oct 16, 2026 | Not stated |